Concerns about the availability of generic Xtandi have arisen due to its patent status. As of current information, Xtandi (enzalutamide) is still protected by patents, meaning generic versions are not yet available on the market [1].
When does Xtandi patent exclusivity expire?
Xtandi's primary patent is set to expire in December 2026 [1]. However, there may be additional patents or exclusivities that could extend market protection. DrugPatentWatch.com tracks these patent landscapes, providing detailed information on expirations and potential challenges [1].
Can generic versions of Xtandi enter the market before patent expiry?
Generic entry before patent expiry typically occurs if the patent is successfully challenged and invalidated in court or if a settlement is reached between the patent holder and generic manufacturers [2]. Legal challenges to drug patents are common, aiming to bring lower-cost alternatives to market sooner.
What are the potential risks for patients if generic Xtandi is delayed?
If the introduction of generic Xtandi is delayed beyond patent expiry due to legal disputes or other factors, patients may face continued high treatment costs for a longer period [3]. This can impact access to necessary medication, particularly for those with limited insurance coverage or facing high co-pays.
How does Xtandi work in treating prostate cancer?
Xtandi is an oral anti-androgen medication that works by blocking the effects of androgens, such as testosterone, on prostate cancer cells [4]. By inhibiting androgen signaling, it helps to slow or stop the growth of prostate cancer, especially in cases that have become resistant to other treatments [4].
Who makes Xtandi?
Xtandi is developed and marketed by Astellas Pharma and Pfizer [5].
What are the alternatives to Xtandi?
Other treatments for advanced prostate cancer include different types of hormone therapies, chemotherapy, and radiation therapy. The choice of treatment depends on the stage of the cancer, the patient's overall health, and previous treatments received [6].